跳至主要内容
临床试验/NCT02235675
NCT02235675已完成不适用

Prospective, Multicenter Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study for Infrapopliteal Arteries Using the Tack-It Endovascular System™

Philips Clinical & Medical Affairs Global2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2013年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
35
试验地点
2
主要终点
Primary Endpoints

研究概览

简要总结

Multi-center study to optimize below the knee (BTK) balloon angioplasty results by creating tissue apposition in peripheral arteries with Reference Vessel Diameter's (RVD) ranging from 1.5mm to 4.5mm.

详细描述

This first in man (FIM) study is to collect data in support of the safety and performance of the Intact Vascular Tack-It Endovascular System™ for tissue apposition to optimize balloon angioplasty.

Study primary endpoints:

Safety: Composite of Major Adverse Limb Events (MALE) and Peri-procedural Death (POD), assessed at 1 month. Endpoint includes any of the following:

  • Major amputation - amputation above the ankle
  • Re-intervention (surgical or endovascular) in the target limb
  • Procedure-related death - any death within 1 month of the index procedure or any MALE

Device Success: The achievement of successful delivery and deployment of the study device(s) at the intended target site(s) and successful withdrawal of the delivery catheter.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age of subject is >18
  • Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the consent form
  • Subject has critical limb ischemia (CLI)
  • Subject has Rutherford Clinical Category 4-
  • (hemodynamic reference)
  • Reference vessel diameter below the knee (BTK) is between 1.5mm and 4.5mm (inclusive).
  • De-novo target lesion(s) has stenosis >70%.
  • Must be able to perform PTA. The PTA must result in a dissection Type A - F at some location along the treatment site.
  • Any vessel intervened on must have distal reconstitution above the ankle.
  • Inflow Iliac, SFA and Popliteal lesions can be treated during the same procedure using standard angioplasty and/or an approved device. These inflow lesions must be treated first, prior to consideration of treatment of BTK lesions. The patient can be enrolled if the inflow lesions are treated with good angiographic results (must have <30% residual stenosis and no evidence of embolization).

排除标准

  • The subject has a lesion on the plantar surface of the heel or over the Achilles tendon or has exposed calcaneus.
  • The subject has extensive forefoot gangrene / ischemic ulcer that cannot be resolved with standard metatarsal amputation.
  • Previous treatment failure of inflow arteries (Iliac, SFA and Popliteal)
  • Subject with below knee bypass.
  • Subject has significant stenosis or occlusion of inflow vessels tract (proximal disease) not successfully treated (>30% residual stenosis and/or complication of the procedure) prior to BTK angioplasty and patient enrollment.
  • Subject is permanently wheel-chair bound or bedridden.
  • Subject has an allergy to contrast medium that cannot be pretreated.
  • Episode of acute limb ischemia within the previous 30 days.
  • Subject is undergoing atherectomy in the target limb or cryoplasty or stenting of BTK treatment site.
  • Subject has a systemic infection with positive blood cultures/bacteremia within one week.
  • Subject has undrained pus or spreading wet gangrene in the foot that is not controlled at the time of revascularization procedure.
  • Subject in whom antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated.
  • Myocardial infarction within 30 days prior to enrollment.
  • History of stroke within 180 days prior to enrollment.
  • Subject has acute or chronic renal disease (e.g., as measured by a serum creatinine of >2.5 mg/dL or >220 umol/L).
  • Subject has a known hypersensitivity or contraindication to nitinol.

结局指标

主要结局

Primary Endpoints

时间窗: 30 Days

Safety: Composite of Major Adverse Limb Events (MALE) and Peri-procedural Death (POD), assessed at 1 month. Endpoint includes any of the following: * Major amputation - amputation above the ankle * Re-intervention (surgical or endovascular) in the target limb * Procedure-related death - any death within 1 month of the index procedure or any MALE

次要结局

  • Secondary Endpoints(1, 3, 6 and 12 Months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验